The EMA recommended that NUZ-001, formerly monepantel, be granted orphan medicinal product designation to treat ALS in Europe ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Clinuvel Pharmaceuticals is in advanced discussions with the ...

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

It also has a marketing application to the European Medicines Agency, with a decision expected in 2025. BridgeBio has granted ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

The European Medicines Agency said Thursday that its committee evaluating medical products has recommended partial approval ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...

ImmunityBio (IBRX) announced new data from its ongoing QUILT 3.032 study. As of November, 100 patients with Bacillus Calmette-Guerin, or ...